{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:42:42Z","timestamp":1792802562622,"version":"4.5.0"},"reference-count":72,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2020,4,23]],"date-time":"2020-04-23T00:00:00Z","timestamp":1587600000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Kinetoplastid parasites, including Leishmania and Trypanosoma spp., are life threatening pathogens with a worldwide distribution. Next-generation therapeutics for treatment are needed as current treatments have limitations, such as toxicity and drug resistance. In this study, we examined the activities of established mammalian target of rapamycin (mTOR)\/phosphoinositide 3-kinase (PI3K) inhibitors against these tropical diseases. High-throughput screening of a library of 1742 bioactive compounds against intracellular L. donovani was performed, and seven mTOR\/PI3K inhibitors were identified. Dose-dilution assays revealed that these inhibitors had half maximal effective concentration (EC50) values ranging from 0.14 to 13.44 \u03bcM for L. donovani amastigotes and from 0.00005 to 8.16 \u03bcM for T. brucei. The results of a visceral leishmaniasis mouse model indicated that treatment with Torin2, dactolisib, or NVP-BGT226 resulted in reductions of 35%, 53%, and 54%, respectively, in the numbers of liver parasites. In an acute T. brucei mouse model using NVP-BGT226 parasite numbers were reduced to under the limits of detection by five consecutive days of treatment. Multiple sequence and structural alignment results indicated high similarities between mTOR and kinetoplastid TORs; the inhibitors are predicted to bind in a similar manner. Taken together, these results indicated that the TOR pathways of parasites have potential for the discovery of novel targets and new potent inhibitors.<\/jats:p>","DOI":"10.3390\/molecules25081980","type":"journal-article","created":{"date-parts":[[2020,4,29]],"date-time":"2020-04-29T01:24:18Z","timestamp":1588123458000},"page":"1980","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["In Vitro and in Vivo Activity of mTOR Kinase and PI3K Inhibitors Against Leishmania donovani and Trypanosoma brucei"],"prefix":"10.3390","volume":"25","author":[{"given":"Trong-Nhat","family":"Phan","sequence":"first","affiliation":[{"name":"Leishmania Research Laboratory, Institut Pasteur Korea, 696 Sampyeong-dong, Bundang-gu, Seongnam-si, Gyeonggi-do 463\u2013400, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung-Hwa","family":"Baek","sequence":"additional","affiliation":[{"name":"Leishmania Research Laboratory, Institut Pasteur Korea, 696 Sampyeong-dong, Bundang-gu, Seongnam-si, Gyeonggi-do 463\u2013400, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nakyung","family":"Lee","sequence":"additional","affiliation":[{"name":"Screening Development Platform, Institut Pasteur Korea, 696 Sampyeong-dong, Bundang-gu, Seongnam-si, Gyeonggi-do 463\u2013400, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo Young","family":"Byun","sequence":"additional","affiliation":[{"name":"Screening Development Platform, Institut Pasteur Korea, 696 Sampyeong-dong, Bundang-gu, Seongnam-si, Gyeonggi-do 463\u2013400, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Shum","sequence":"additional","affiliation":[{"name":"Screening Development Platform, Institut Pasteur Korea, 696 Sampyeong-dong, Bundang-gu, Seongnam-si, Gyeonggi-do 463\u2013400, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joo Hwan","family":"No","sequence":"additional","affiliation":[{"name":"Leishmania Research Laboratory, Institut Pasteur Korea, 696 Sampyeong-dong, Bundang-gu, Seongnam-si, Gyeonggi-do 463\u2013400, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,4,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1172\/JCI33945","article-title":"Kinetoplastids: Related protozoan pathogens, different diseases","volume":"118","author":"Stuart","year":"2008","journal-title":"J. Clin. Investig."},{"key":"ref_2","unstructured":"World Health Organization (2020, April 23). Leishmaniasis. Fact sheet No. 375, 2017. World Health Organization. Available online: http:\/\/www.who.int\/mediacentre\/factsheets\/fs375\/en\/."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S0035-9203(00)90055-5","article-title":"Visceral leishmaniasis control: A public health perspective","volume":"94","author":"Boelaert","year":"2000","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"ref_4","unstructured":"World Health Organization (2010). Control of the Leishmaniases, WHO. WHO Technical Report Series 949."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Alvar, J., Velez, I.D., Bern, C., Herrero, M., Desjeux, P., Cano, J., Jannin, J., and Boer, M.D. (2012). Leishmaniasis Worldwide and Global Estimates of Its Incidence. PLOS ONE, 7.","DOI":"10.1371\/journal.pone.0035671"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.7554\/eLife.02851","article-title":"Global distribution maps of the leishmaniases","volume":"3","author":"Pigott","year":"2014","journal-title":"eLife"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.actatropica.2015.12.016","article-title":"Visceral leishmaniasis: Revisiting current treatments and approaches for future discoveries","volume":"155","author":"No","year":"2016","journal-title":"Acta Trop."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"586","DOI":"10.4269\/ajtmh.1996.55.586","article-title":"The Efficacy of Pentamidine in the Treatment of Early-Late Stage Trypanosoma brucei gambiense Trypanosomiasis *","volume":"55","author":"Doua","year":"1996","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S1474-4422(12)70296-X","article-title":"Clinical features, diagnosis, and treatment of human African trypanosomiasis (sleeping sickness)","volume":"12","author":"Kennedy","year":"2013","journal-title":"Lancet Neurol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1093\/cid\/cis886","article-title":"Nifurtimox-Eflornithine Combination Therapy for Second-Stage Gambiense Human African Trypanosomiasis: M\u00e9decins Sans Fronti\u00e8res Experience in the Democratic Republic of the Congo","volume":"56","author":"Alirol","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1016\/S1473-3099(19)30612-7","article-title":"New WHO guidelines for treatment of gambiense human African trypanosomiasis including fexinidazole: Substantial changes for clinical practice","volume":"20","author":"Lindner","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ejim.2017.05.001","article-title":"Chagas disease in Europe: A review for the internist in the globalized world","volume":"43","author":"Antinori","year":"2017","journal-title":"Eur. J. Intern. Med."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Zulantay, I., Apt, W., Ramos, D., Godoy, L., Valencia, C., Molina, M., Sepulveda, E., Thieme, P., Martinez, G., and Corral, G. (2013). The Epidemiological Relevance of Family Study in Chagas Disease. PLOS Neglected Trop. Dis., 7.","DOI":"10.1371\/journal.pntd.0001959"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.pt.2008.04.006","article-title":"Ever-increasing complexities of diamidine and arsenical crossresistance in African trypanosomes","volume":"24","year":"2008","journal-title":"Trends Parasitol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s40265-013-0069-4","article-title":"Amphotericin B Formulations: A Comparative Review of Efficacy and Toxicity","volume":"73","author":"Hamill","year":"2013","journal-title":"Drugs"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Ponte-Sucre, A., Gamarro, F., Dujardin, J.-C., Barrett, M.P., Lopez-V\u00e9lez, R., Garc\u00eda-Hern\u00e1ndez, R., Pountain, A.W., Mwenechanya, R., and Papadopoulou, B. (2017). Drug resistance and treatment failure in leishmaniasis: A 21st century challenge. PLOS Neglected Trop. Dis., 11.","DOI":"10.1371\/journal.pntd.0006052"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"5022","DOI":"10.1073\/pnas.0711014105","article-title":"A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes","volume":"105","author":"Wilkinson","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1191\/0960327106het653oa","article-title":"Toxic side effects of drugs used to treat Chagas\u2019 disease (American trypanosomiasis)","volume":"25","author":"Castro","year":"2006","journal-title":"Hum. Exp. Toxicol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/nrmicro1748","article-title":"Visceral leishmaniasis: What are the needs for diagnosis, treatment and control?","volume":"5","author":"Chappuis","year":"2007","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_20","unstructured":"(2020, April 23). Human African Trypanosomiasis: A Guide for Drug Supply, 2002. World Health Organization. Available online: https:\/\/apps.who.int\/iris\/handle\/10665\/67252."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0020-7519(00)00043-6","article-title":"Anti-malarial effect of histone deacetylation inhibitors and mammalian tumour cytodifferentiating agents","volume":"30","author":"Andrews","year":"2000","journal-title":"Int. J. Parasitol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"13554","DOI":"10.1074\/jbc.M413556200","article-title":"Resistance to a Protein Farnesyltransferase Inhibitor inPlasmodium falciparum","volume":"280","author":"Eastman","year":"2005","journal-title":"J. Boil. Chem."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/nature08893","article-title":"N-myristoyltransferase inhibitors as new leads to treat sleeping sickness","volume":"464","author":"Frearson","year":"2010","journal-title":"Nat."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.4155\/fmc.11.92","article-title":"Target repurposing for neglected diseases","volume":"3","author":"Pollastri","year":"2011","journal-title":"Futur. Med. Chem."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1242\/jcs.051011","article-title":"mTOR signaling at a glance","volume":"122","author":"Laplante","year":"2009","journal-title":"J. Cell Sci."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.ceb.2005.09.009","article-title":"Growing roles for the mTOR pathway","volume":"17","author":"Sarbassov","year":"2005","journal-title":"Curr. Opin. Cell Boil."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.cell.2006.01.016","article-title":"TOR Signaling in Growth and Metabolism","volume":"124","author":"Wullschleger","year":"2006","journal-title":"Cell"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.dnarep.2004.04.002","article-title":"PI 3-kinase related kinases: \u2018Big\u2019 players in stress-induced signaling pathways","volume":"3","author":"Abraham","year":"2004","journal-title":"DNA Repair"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.cell.2004.06.023","article-title":"Initiating Cellular Stress Responses","volume":"118","author":"Bakkenist","year":"2004","journal-title":"Cell"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1126\/science.270.5233.50","article-title":"PIK-Related Kinases: DNA Repair, Recombination, and Cell Cycle Checkpoints","volume":"270","author":"Keith","year":"1995","journal-title":"Sci."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.semcancer.2019.07.009","article-title":"PI3K\/Akt\/mTOR inhibitors in cancer: At the bench and bedside","volume":"59","author":"Alzahrani","year":"2019","journal-title":"Semin. Cancer Boil."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.cell.2017.07.029","article-title":"The PI3K Pathway in Human Disease","volume":"170","author":"Fruman","year":"2017","journal-title":"Cell"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Hillmann, P., and Fabbro, D. (2019). PI3K\/mTOR Pathway Inhibition: Opportunities in Oncology and Rare Genetic Diseases. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20225792"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1146\/annurev-med-062913-051343","article-title":"The PI3K\/AKT Pathway as a Target for Cancer Treatment","volume":"67","author":"Mayer","year":"2016","journal-title":"Annu. Rev. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12943-019-0954-x","article-title":"Targeting PI3K in cancer: Mechanisms and advances in clinical trials","volume":"18","author":"Yang","year":"2019","journal-title":"Mol. Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrclinonc.2018.28","article-title":"Targeting the PI3K pathway in cancer: Are we making headway?","volume":"15","author":"Janku","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Diaz-Gonzalez, R., Kuhlmann, F.M., Galan-Rodriguez, C., da Silva, L.M., Saldivia, M., Karver, C.E., Rodriguez, A., Beverley, S.M., Navarro, M., and Pollastri, M.P. (2011). The susceptibility of trypanosomatid pathogens to PI3\/mTOR kinase inhibitors affords a new opportunity for drug repurposing. PLoS Negl Trop Dis., 5.","DOI":"10.1371\/journal.pntd.0001297"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1093\/jac\/dkw448","article-title":"Pharmacological inhibition of p110delta subunit of PI3K confers protection against experimental leishmaniasis","volume":"72","author":"Khadem","year":"2017","journal-title":"J. Antimicrob Chemother."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Khadir, F., Shaler, C.R., Oryan, A., Rudak, P.T., Mazzuca, D.M., Taheri, T., Dikeakos, J.D., Haeryfar, S.M.M., and Rafati, S. (2018). Therapeutic control of leishmaniasis by inhibitors of the mammalian target of rapamycin. PLOS Neglected Trop. Dis., 12.","DOI":"10.1371\/journal.pntd.0006701"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"14579","DOI":"10.1073\/pnas.0802668105","article-title":"Rapamycin inhibits trypanosome cell growth by preventing TOR complex 2 formation","volume":"105","author":"Barquilla","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"697","DOI":"10.4161\/cc.8.5.7808","article-title":"Trypanosome TOR complex 2 functions in cytokinesis","volume":"8","author":"Barquilla","year":"2009","journal-title":"Cell Cycle"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"24131","DOI":"10.1074\/jbc.M110.120212","article-title":"Target of Rapamycin (TOR)-like 1 Kinase Is Involved in the Control of Polyphosphate Levels and Acidocalcisome Maintenance in Trypanosoma brucei*","volume":"285","author":"Tonelli","year":"2010","journal-title":"J. Boil. Chem."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"11965","DOI":"10.1073\/pnas.1004599107","article-title":"Expansion of the target of rapamycin (TOR) kinase family and function in Leishmania shows that TOR3 is required for acidocalcisome biogenesis and animal infectivity","volume":"107","author":"Beverley","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1021\/jm101520v","article-title":"Discovery of 9-(6-Aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a Potent, Selective, and Orally Available Mammalian Target of Rapamycin (mTOR) Inhibitor for Treatment of Cancer","volume":"54","author":"Liu","year":"2011","journal-title":"J. Med. Chem."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1158\/1535-7163.MCT-08-0017","article-title":"Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase\/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity","volume":"7","author":"Maira","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/nchembio.117","article-title":"Targeted polypharmacology: Discovery of dual inhibitors of tyrosine and phosphoinositide kinases","volume":"4","author":"Apsel","year":"2008","journal-title":"Nat. Methods"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/nature10912","article-title":"The translational landscape of mTOR signalling steers cancer initiation and metastasis","volume":"485","author":"Hsieh","year":"2012","journal-title":"Nature"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1158\/1535-7163.MCT-09-0954","article-title":"Antitumor Efficacy Profile of PKI-402, a Dual Phosphatidylinositol 3-Kinase\/Mammalian Target of Rapamycin Inhibitor","volume":"9","author":"Mallon","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1093\/annonc\/mds011","article-title":"Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors","volume":"23","author":"Markman","year":"2012","journal-title":"Ann. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1158\/0008-5472.CAN-09-2340","article-title":"Beyond Rapalog Therapy: Preclinical Pharmacology and Antitumor Activity of WYE-125132, an ATP-Competitive and Specific Inhibitor of mTORC1 and mTORC2","volume":"70","author":"Yu","year":"2010","journal-title":"Cancer Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S1471-4922(00)01829-8","article-title":"New drugs for the treatment of human African trypanosomiasis: Research and development","volume":"17","author":"Keiser","year":"2001","journal-title":"Trends Parasitol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1021\/jm500361r","article-title":"Establishment of a Structure\u2013Activity Relationship of 1H-Imidazo[4,5-c]quinoline-Based Kinase Inhibitor NVP-BEZ235 as a Lead for African Sleeping Sickness","volume":"57","author":"Seixas","year":"2014","journal-title":"J. Med. Chem."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.7150\/ijbs.25488","article-title":"Simultaneously targeting DNA damage repair pathway and mTORC1\/2 results in small cell lung cancer growth arrest via ER stress-induced apoptosis","volume":"14","author":"Fang","year":"2018","journal-title":"Int J. Biol Sci."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1002\/pbc.24989","article-title":"Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program","volume":"61","author":"Kang","year":"2014","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1158\/2159-8290.CD-15-1481","article-title":"Integrin-\u03b110 Dependency Identifies RAC and RICTOR as Therapeutic Targets in High-Grade Myxofibrosarcoma","volume":"6","author":"Okada","year":"2016","journal-title":"Cancer Discov."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s10549-018-05104-9","article-title":"Synergistic anti-cancer activity of CDK4\/6 inhibitor palbociclib and dual mTOR kinase inhibitor MLN0128 in pRb-expressing ER-negative breast cancer","volume":"174","author":"Yamamoto","year":"2019","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1093\/jac\/dku422","article-title":"Nitroimidazo-oxazole compound DNDI-VL-2098: An orally effective preclinical drug candidate for the treatment of visceral leishmaniasis","volume":"70","author":"Gupta","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/nature19339","article-title":"Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness","volume":"537","author":"Khare","year":"2016","journal-title":"Nat."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"AAC.00079\u201318","DOI":"10.1128\/AAC.00079-18","article-title":"Leishmania donovani Parasites Are Inhibited by the Benzoxaborole AN2690 Targeting Leucyl-tRNA Synthetase","volume":"62","author":"Manhas","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"9615","DOI":"10.1021\/acs.jmedchem.5b01456","article-title":"Novel Amino-pyrazole Ureas with Potent In Vitro and In Vivo Antileishmanial Activity","volume":"58","author":"Mowbray","year":"2015","journal-title":"J. Med. Chem."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"334","DOI":"10.7554\/eLife.09744","article-title":"The anti-tubercular drug delamanid as a potential oral treatment for visceral leishmaniasis","volume":"5","author":"Patterson","year":"2016","journal-title":"eLife"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"6281","DOI":"10.1128\/AAC.00352-16","article-title":"A Novel Spirooxindole Derivative Inhibits the Growth of Leishmania donovani Parasites both In Vitro and In Vivo by Targeting Type IB Topoisomerase","volume":"60","author":"Saha","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ccr.2012.06.001","article-title":"The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma","volume":"22","author":"Berry","year":"2012","journal-title":"Cancer Cell"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"7116","DOI":"10.1158\/1078-0432.CCR-11-0796","article-title":"Novel Phosphoinositide 3-Kinase\/mTOR Dual Inhibitor, NVP-BGT226, Displays Potent Growth-Inhibitory Activity against Human Head and Neck Cancer Cells In Vitro and In Vivo","volume":"17","author":"Chang","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Myburgh, E., Coles, J.A., Ritchie, R., Kennedy, P.G.E., McLatchie, A.P., Rodgers, J., Taylor, M.C., Barrett, M.P., Brewer, J.M., and Mottram, J.C. (2013). In Vivo Imaging of Trypanosome-Brain Interactions and Development of a Rapid Screening Test for Drugs against CNS Stage Trypanosomiasis. PLOS Neglected Trop. Dis., 7.","DOI":"10.1371\/journal.pntd.0002384"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Siqueira-Neto, J., Moon, S., Jang, J., Yang, G., Lee, C., Moon, H.K., Chatelain, E., Genovesio, A., Cechetto, J., and Freitas-Junior, L.H. (2012). An Image-Based High-Content Screening Assay for Compounds Targeting Intracellular Leishmania donovani Amastigotes in Human Macrophages. PLOS Neglected Trop. Dis., 6.","DOI":"10.1371\/journal.pntd.0001671"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"3855","DOI":"10.1128\/AAC.00548-09","article-title":"In Vitro Susceptibilities of Leishmania donovani Promastigote and Amastigote Stages to Antileishmanial Reference Drugs: Practical Relevance of Stage-Specific Differences","volume":"53","author":"Vermeersch","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1021\/acsinfecdis.5b00068","article-title":"In Vitro and in Vivo Activity of Multitarget Inhibitors against Trypanosoma brucei","volume":"1","author":"Yang","year":"2015","journal-title":"ACS Infect. Dis."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.ijpddr.2012.02.002","article-title":"Application of a resazurin-based high-throughput screening assay for the identification and progression of new treatments for human African trypanosomiasis","volume":"2","author":"Bowling","year":"2012","journal-title":"Int. J. Parasitol. Drugs Drug Resist."},{"key":"ref_70","unstructured":"Stauber, L.A. (1955). Leishmaniasis in the hamster. Some Physiological Aspects and Consequences of Parasitism, Rutgers University Press."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1126\/science.273.5272.239","article-title":"Structure of the FKBP12-Rapamycin Complex Interacting with Binding Domain of Human FRAP","volume":"273","author":"Choi","year":"1996","journal-title":"Science"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/sj.onc.1210693","article-title":"Structural characterization of the interaction of mTOR with phosphatidic acid and a novel class of inhibitor: Compelling evidence for a central role of the FRB domain in small molecule-mediated regulation of mTOR","volume":"27","author":"Veverka","year":"2007","journal-title":"Oncogene"}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/25\/8\/1980\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T14:09:10Z","timestamp":1760364550000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/25\/8\/1980"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,23]]},"references-count":72,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,4]]}},"alternative-id":["molecules25081980"],"URL":"https:\/\/doi.org\/10.3390\/molecules25081980","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,23]]}}}